{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-108333","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.855207+00:00","generated_at":"2026-05-15T11:48:33.888073+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CRISPR Therapeutics completes $600M convertible note offering due 2031","bullets":["Issued $600M aggregate principal of Convertible Senior Notes due 2031; net proceeds ~$585.2M.","Effective coupon 1.125%; increased to 1.7308% due to anticipated Swiss withholding tax.","Initial conversion price ~$76.56 per share, a 45% premium to the $52.80 closing price on March 10, 2026.","Notes mature March 1, 2031; unregistered, sold to QIBs under Rule 144A; proceeds for general corporate purposes.","Holders may convert at any time before maturity; company may redeem after March 6, 2029 if stock price condition met."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-108333","json":"https://secwatch.observer/filing/0001193125-26-108333.json","markdown":"https://secwatch.observer/filing/0001193125-26-108333.md","text":"https://secwatch.observer/filing/0001193125-26-108333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/crsp-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:48:33.888073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"446d0629ab6639aa5efc249a5ae582213f76a1ff","claim":"CRISPR Therapeutics AG incurred convertible notes of $600.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at effective coupon of 1.125%, increased to 1.7308% maturing March 1, 2031.","evidence_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","confidence":0.9},{"claim_id":"fbb4a778578d8899f2feae408f3919c0743e8928","claim":"CRISPR Therapeutics AG entered into Indenture with U.S. Bank Trust Company, National Association valued at $600.0 million aggregate principal amount (effective 2026-03-16).","evidence_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-054183","ticker":"EMAT","company_name":"Evolution Metals & Technologies Corp.","filed_at":"2026-05-11T23:59:59+00:00","headline":"EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued","event_type":"debt","sec_items":["1.01","2.03","3.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054183","json":"https://secwatch.observer/filing/0001213900-26-054183.json","markdown":"https://secwatch.observer/filing/0001213900-26-054183.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/ea0290073-8k_evolution.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","comparable_excerpt":"The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm"}},{"accession":"0001213900-26-053894","ticker":"TBH","company_name":"Brag House Holdings, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053894","json":"https://secwatch.observer/filing/0001213900-26-053894.json","markdown":"https://secwatch.observer/filing/0001213900-26-053894.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/ea0289773-8k_braghouse.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","comparable_excerpt":"The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm"}},{"accession":"0001492691-26-000042","ticker":"KNX","company_name":"Knight-Swift Transportation Holdings Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001492691-26-000042","json":"https://secwatch.observer/filing/0001492691-26-000042.json","markdown":"https://secwatch.observer/filing/0001492691-26-000042.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/knx-20260505.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","comparable_excerpt":"On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the \"Company\") completed its previously announced private offering (the \"Offering\") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm"}},{"accession":"0001104659-26-057128","ticker":"PUMP","company_name":"ProPetro Holding Corp.","filed_at":"2026-05-07T23:59:59+00:00","headline":"ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057128","json":"https://secwatch.observer/filing/0001104659-26-057128.json","markdown":"https://secwatch.observer/filing/0001104659-26-057128.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/tm2613899d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","comparable_excerpt":"On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm"}},{"accession":"0001104659-26-057138","ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan","event_type":"debt","sec_items":["1.01","1.02","2.02","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057138","json":"https://secwatch.observer/filing/0001104659-26-057138.json","markdown":"https://secwatch.observer/filing/0001104659-26-057138.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/tm2613898d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","comparable_excerpt":"On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm"}},{"accession":"0001360604-26-000047","ticker":"HR","company_name":"Healthcare Realty Trust Inc","filed_at":"2026-05-07T23:59:59+00:00","headline":"HR subsidiary issues $700M 3.00% exchangeable senior notes due 2032","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001360604-26-000047","json":"https://secwatch.observer/filing/0001360604-26-000047.json","markdown":"https://secwatch.observer/filing/0001360604-26-000047.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/0001360604-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/hr-20260507.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","comparable_excerpt":"issued $700,000,000 aggregate principal amount of its 3.00% Exchangeable Senior Notes due 2032","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/0001360604-26-000047-index.htm"}},{"accession":"0001140361-26-023577","ticker":"TCPC","company_name":"BlackRock TCP Capital Corp.","filed_at":"2026-06-01T20:50:02+00:00","headline":"BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities","event_type":"debt","sec_items":["1.01","1.02","2.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023577","json":"https://secwatch.observer/filing/0001140361-26-023577.json","markdown":"https://secwatch.observer/filing/0001140361-26-023577.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/ef20075169_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","comparable_excerpt":"Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the \" Closing Date \"), BlackRock TCP Capital Corp. (the \" Company \"), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the \" CLO Transaction \"). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm"}},{"accession":"0001628280-26-039479","ticker":"VVX","company_name":"V2X, Inc.","filed_at":"2026-06-01T20:10:20+00:00","headline":"V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039479","json":"https://secwatch.observer/filing/0001628280-26-039479.json","markdown":"https://secwatch.observer/filing/0001628280-26-039479.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/0001628280-26-039479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/vec-20260529.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm","comparable_excerpt":"The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/0001628280-26-039479-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}